Responses
Clinical/translational cancer immunotherapy
Original research
Bispecific antibody CD73xEGFR more selectively inhibits the CD73/adenosine immune checkpoint on cancer cells and concurrently counteracts pro-oncogenic activities of CD73 and EGFR
Compose a Response to This Article
Other responses
No responses have been published for this article.
